12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Shire sales and marketing update

Shire launched Intuniv guanfacine extended release in Canada as monotherapy to treat ADHD in patients ages six to 12...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >